MX2010003060A - Inhibidores de la interaccion entre mdm2 y p53. - Google Patents

Inhibidores de la interaccion entre mdm2 y p53.

Info

Publication number
MX2010003060A
MX2010003060A MX2010003060A MX2010003060A MX2010003060A MX 2010003060 A MX2010003060 A MX 2010003060A MX 2010003060 A MX2010003060 A MX 2010003060A MX 2010003060 A MX2010003060 A MX 2010003060A MX 2010003060 A MX2010003060 A MX 2010003060A
Authority
MX
Mexico
Prior art keywords
sup
mdm2
interaction
inhibitors
compounds
Prior art date
Application number
MX2010003060A
Other languages
English (en)
Inventor
Sophie Coupa
Virginie Sophie Poncelet
Bruno Schoentjes
Pierre-Henri Storck
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38910911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003060(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2010003060A publication Critical patent/MX2010003060A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invenci?n proporciona compuestos de f?rmula (I), su uso como inhibidores de una interacci?n p53-MDM2 as? como las composiciones farmac?uticas que comprenden a dichos compuestos: (ver f?rmula I) en donde n, m, p, s, t, R1, R2, R3, R4, R5, R6, R7, R20, X, Y, Q y Z tienen los significados definidos.
MX2010003060A 2007-09-21 2008-09-18 Inhibidores de la interaccion entre mdm2 y p53. MX2010003060A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116889 2007-09-21
PCT/EP2008/062433 WO2009037308A1 (en) 2007-09-21 2008-09-18 Inhibitors of the interaction between mdm2 and p53

Publications (1)

Publication Number Publication Date
MX2010003060A true MX2010003060A (es) 2010-04-07

Family

ID=38910911

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003060A MX2010003060A (es) 2007-09-21 2008-09-18 Inhibidores de la interaccion entre mdm2 y p53.

Country Status (23)

Country Link
US (4) US9573933B2 (es)
EP (1) EP2203440B1 (es)
JP (1) JP5438007B2 (es)
CN (2) CN104761541A (es)
AR (1) AR068627A1 (es)
AT (1) ATE502934T1 (es)
AU (1) AU2008300527B2 (es)
BR (1) BRPI0817223B8 (es)
CA (1) CA2699849C (es)
CL (1) CL2008002798A1 (es)
DE (1) DE602008005784D1 (es)
DK (1) DK2203440T3 (es)
ES (1) ES2363838T3 (es)
HR (1) HRP20110394T1 (es)
JO (1) JO2704B1 (es)
MX (1) MX2010003060A (es)
PA (1) PA8796901A1 (es)
PE (1) PE20090817A1 (es)
RU (1) RU2477724C2 (es)
SI (1) SI2203440T1 (es)
TW (1) TWI434841B (es)
UY (1) UY31349A1 (es)
WO (1) WO2009037308A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
NZ594186A (en) 2009-02-04 2012-12-21 Janssen Pharmaceutica Nv Indole derivatives as anticancer agents
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN102321034B (zh) * 2011-06-07 2014-08-13 中国人民解放军第二军医大学 硫代苯二氮卓类化合物及其作为药物的用途
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
ES2410704B1 (es) * 2011-11-28 2014-04-29 Universitat De Barcelona Indoleninas fluoradas útiles para el tratamiento del cáncer.
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
CN110290764B (zh) 2016-12-21 2022-04-29 特里弗洛心血管公司 心脏瓣膜支撑装置及用于制造和使用该装置的方法
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
EP1379239B1 (en) * 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
WO2003040402A2 (en) * 2001-11-09 2003-05-15 The Regents Of The University Of California Alpha-helix mimicry by a class of organic molecules
SE0400284D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
US7540139B2 (en) * 2004-08-16 2009-06-02 Rowse Hydraulic Rakes Co., Inc. Foldable hay rake
KR101331786B1 (ko) * 2004-09-22 2013-11-21 얀센 파마슈티카 엔.브이. Ｍｄｍ2 및 ｐ53간의 상호작용 저해제
EP1865963A2 (en) * 2005-02-18 2007-12-19 Acadia Pharmaceuticals Inc. Triazadibenzoazulene compounds useful for the treatment and prevention of pain and screening methods therefor
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
EP2001868B1 (en) 2006-03-22 2013-07-17 Janssen Pharmaceutica N.V. Inhibitors of the interaction between mdm2 and p53
TW200922557A (en) * 2007-08-06 2009-06-01 Janssen Pharmaceutica Nv Substituted phenylenediamines as inhibitors of the interaction between MDM2 and p53
JO2704B1 (en) 2007-09-21 2013-03-03 جانسين فارماسوتيكا ان في Interference inhibition factors between MD2 and B53

Also Published As

Publication number Publication date
CA2699849C (en) 2015-10-27
US20180263966A1 (en) 2018-09-20
BRPI0817223B1 (pt) 2020-04-07
PA8796901A1 (es) 2009-05-15
PE20090817A1 (es) 2009-07-02
JP5438007B2 (ja) 2014-03-12
AU2008300527A1 (en) 2009-03-26
TWI434841B (zh) 2014-04-21
BRPI0817223B8 (pt) 2021-05-25
ATE502934T1 (de) 2011-04-15
BRPI0817223A2 (pt) 2015-03-10
CN101868453A (zh) 2010-10-20
RU2010115765A (ru) 2011-10-27
DE602008005784D1 (de) 2011-05-05
RU2477724C2 (ru) 2013-03-20
EP2203440B1 (en) 2011-03-23
US20200121667A1 (en) 2020-04-23
TW200930709A (en) 2009-07-16
AR068627A1 (es) 2009-11-25
US20100240637A1 (en) 2010-09-23
JP2010539220A (ja) 2010-12-16
US20170112818A1 (en) 2017-04-27
CA2699849A1 (en) 2009-03-26
CL2008002798A1 (es) 2009-06-05
AU2008300527B2 (en) 2013-08-29
ES2363838T3 (es) 2011-08-17
UY31349A1 (es) 2009-03-31
HRP20110394T1 (hr) 2011-06-30
CN104761541A (zh) 2015-07-08
SI2203440T1 (sl) 2011-07-29
DK2203440T3 (da) 2011-06-20
EP2203440A1 (en) 2010-07-07
US9573933B2 (en) 2017-02-21
WO2009037308A1 (en) 2009-03-26
US11583524B2 (en) 2023-02-21
JO2704B1 (en) 2013-03-03

Similar Documents

Publication Publication Date Title
UA91027C2 (ru) ИНГИБИТОРЫ ВЗАИМОДЕЙСТВИЯ МЕЖДУ MDM2 И р53
MX2010003060A (es) Inhibidores de la interaccion entre mdm2 y p53.
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
ATE470665T1 (de) Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
SG154432A1 (en) Quinazolinedione derivatives as parp inhibitors
UA91002C2 (ru) 7-фенилалкилзамещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поле(адф-рибоза)полимеразы
TW200616978A (en) Quinazolinone derivatives as parp inhibitors
MY148634A (en) Pyridazinone derivatives
TW200740761A (en) Histone deacetylase inhibitors
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
IL181271A0 (en) Triazolophthalazine derivatives and pharmaceutical compositions containing the same
HK1128286A1 (en) Heterocyclylalkyl derivatives as inhibitors of histone deacetylase
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
MY153915A (en) Organic compounds
TW200745084A (en) Novel compounds
TNSN08191A1 (en) Kinase inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
PT2049480E (pt) Derivados de 2-arilindole como inibidores da mpges-i
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200738627A (en) Trialkylsilyl-indoles
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53

Legal Events

Date Code Title Description
FG Grant or registration